Bristol Myers Squibb stock: Q3 beat, higher 2026 sales outlook

Bristol Myers Squibb reported third-quarter 2026 results on Thursday, October 29, and raised its full-year revenue outlook after sales exceeded Wall Street expectations. The company also lowered its adjusted earnings guidance because of acquired in-process research and development charges and licensing income, according to the company release.

Growth Portfolio Drives Quarterly Sales

Revenue increased 7 percent year over year to 13.1 billion US dollars in the quarter. Growth portfolio revenue rose 12 percent to 7.7 billion US dollars, while legacy portfolio revenue increased 1 percent as ELIQUIS growth offset declines caused by generic competition in other medicines.

ELIQUIS revenue rose 26 percent to approximately 4.7 billion US dollars, supported by demand, net pricing and market-share gains. The company said the medicine's European loss of exclusivity will pressure fourth-quarter sales, with continued US growth expected to provide a partial offset.

Higher Sales, Lower Adjusted Earnings View

Bristol Myers lifted its 2026 revenue guidance to 49.75 billion to 50.25 billion US dollars from 49 billion to 50 billion US dollars previously. At the same time, the company set adjusted earnings guidance at 6.35 to 6.55 US dollars per share, including a 0.60 US dollar-per-share impact from acquired in-process research and development charges and licensing income.

Third-quarter adjusted diluted earnings were 1.35 US dollars per share and included a 0.58 US dollar-per-share impact from the same items. Management said the underlying business remained supported by the growth portfolio and maintained its expectation for full-year ELIQUIS revenue growth of 20 percent to 25 percent. The full-year legacy portfolio revenue decline is now expected at 3 percent to 5 percent.

Share Price And Investor Focus

Bristol Myers Squibb stock traded at 55.89 euros on Lang & Schwarz at 10:49:19 CEST on Friday, October 30, 2026. The quote gives investors a current market indication, while the revenue outlook and the charge-related earnings reduction define the main balance in the quarterly update. The real-time quote of Bristol Myers Squibb stock is available separately.

The S&P 500 provides the relevant broader US market context for investors following Bristol Myers Squibb and other large-cap healthcare companies: current market reports.

Further pipeline updates, product developments and earnings coverage can be found in more news and analyses on Bristol Myers Squibb stock.